Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, NeuroSense Therapeutics Ltd’s stock clocked out at $2.38, down -4.42% from its previous closing price of $2.49. In other words, the price has decreased by -$4.42 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
To gain a deeper understanding of NRSN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.21 and its Current Ratio is at 2.21. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.00.
Stock Price History:
Over the past 52 weeks, NRSN has reached a high of $2.55, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is 84.49%, while the 200-Day Moving Average is calculated to be 103.88%.
Shares Statistics:
A total of 23.23M shares are outstanding, with a floating share count of 17.38M. Insiders hold about 27.54% of the company’s shares, while institutions hold 0.81% stake in the company.
Earnings Estimates
The current rating of NeuroSense Therapeutics Ltd (NRSN) reflects the combined expertise of 1 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.37 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$0.59 and -$0.59 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.15, with 1.0 analysts recommending between -$0.15 and -$0.15.
